Immediate Impact
1 from Science/Nature 35 standout
Citing Papers
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
2024 Standout
2024 Standout
Works of Weimin Ding being referenced
Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study.
2023
DNA repair factor RAD18 and DNA polymerase Polκ confer tolerance of oncogenic DNA replication stress
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Weimin Ding | 51 | 162 | 99 | 61 | 24 | 287 | |
| Feiteng Lu | 55 | 108 | 97 | 71 | 21 | 280 | |
| Nicole Pinto | 49 | 142 | 93 | 54 | 20 | 256 | |
| Katharina Lisenko | 20 | 103 | 76 | 43 | 24 | 305 | |
| Xing Yang | 100 | 72 | 68 | 38 | 34 | 306 | |
| Esther Yoon | 57 | 84 | 62 | 43 | 25 | 221 | |
| Chong Deng | 35 | 147 | 38 | 146 | 17 | 295 | |
| Haomiao Li | 44 | 156 | 42 | 101 | 27 | 328 | |
| Silvia Sacristán | 50 | 191 | 61 | 68 | 20 | 294 | |
| Qinghua Huang | 35 | 100 | 62 | 47 | 24 | 275 | |
| Yeben Qian | 34 | 150 | 55 | 91 | 24 | 312 |
All Works
Login with ORCID to disown or claim papers
Loading papers...